The studies which are outlined in this proposal represent a very exciting and ambitious plan to address the issues of the magnitude, fine specificity, and precise nature of the autoreactive T cell response in MS and further explore the potential contribution of clonally expanded CSF B cells to disease pathogenesis. Using highly innovative approaches we plan to characterize these responses at a single cell level and analyze the TCR usage and CSF B cell repertoire, specifically in the context of various therapeutic interventions. These studies will determine the effectiveness of immune reconstitution with respect to the response to myelin antigens and compare that with what happens to the immune response following more standard immune suppression using mitoxantrone. We will also be able to compare this information with the data we are generating on patients with RRMS receiving more standard immunomodulatory therapies. We anticipate that these studies will provide important information with regard to the immunopathogenesis of MS. Data from these studies will allow the PI to design clinical trials testing novel therapeutic agents for MS based on the translational studies. In addition, the proposed Award will allow the PI to concentrate his efforts on mentoring the next generation of clinician scientists focusing their efforts on multiple sclerosis. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24NS044250-06
Application #
7238737
Study Section
NST-2 Subcommittee (NST)
Program Officer
Utz, Ursula
Project Start
2003-05-15
Project End
2009-04-30
Budget Start
2007-05-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$128,911
Indirect Cost
Name
Ohio State University
Department
Neurology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Smith, Kristen M; Guerau-de-Arellano, Mireia; Costinean, Stefan et al. (2012) miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 189:1567-76
Lovett-Racke, Amy E; Yang, Yuhong; Racke, Michael K (2011) Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 1812:246-51
Guerau-de-Arellano, Mireia; Smith, Kristen M; Godlewski, Jakub et al. (2011) Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 134:3578-89
Yang, Yuhong; Liu, Yue; Wei, Ping et al. (2010) Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol 67:498-507
Guerau-de-Arellano, Mireia; Lovett-Racke, Amy E; Racke, Michael K (2010) miRNAs in multiple sclerosis: regulating the regulators. J Neuroimmunol 229:3-4
Boster, Aaron; Racke, Michael K (2009) Pharmacotherapy of multiple sclerosis: the PROOF trial. Expert Opin Pharmacother 10:1235-7
Cameron, Elizabeth M; Spencer, Sade; Lazarini, Jonathan et al. (2009) Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol 213:123-30
Stüve, O; Cravens, P D; Frohman, E M et al. (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72:396-401
Gocke, Anne R; Hussain, Rehana Z; Yang, Yuhong et al. (2009) Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol 182:4479-87
Yang, Yuhong; Weiner, Jeffrey; Liu, Yue et al. (2009) T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med 206:1549-64

Showing the most recent 10 out of 33 publications